Bristol-Myers partnered with the J. David Gladstone Institutes to identify and validate targets that affect tau dysfunction in Alzheimer's disease (AD)

Bristol-Myers Squibb Co.

U.S. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

The J. David Gladstone Institutes

U.S. / Non-Profit or Major Disease Foundation

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced